Interested in Low-code and CRM Technology? Download our FREE whitepaper on Low-code CRM. This is an exclusive promotion being run on LinkedIn.

  Please register (it's free!) or login to view the remaining preview.
If you are logged in, your referral link [?] is automatically included below.
EMBED CODE (Copy and Paste)


DOCUMENT DESCRIPTION

Yielding an mPFS of 6.9 months and MOS of 14.6 months, the Stupp regimen has been the efficacy yardstick and standard treatment protocol followed for newly diagnosed glioblastoma patients. However, this patient segment will witness substantial changes with the introduction of three new immunotherapeutic agents--dendritic-cell vaccines DCVax-L and ICT-107 and PD-1 inhibitor Opdivo-- in the near future

Market growth drivers over the next five years and afterward will be the approval and extension, as well as rapid uptake of, Opdivo in combination with the current standard of care for treatment of all eligible newly diagnosed patients, garnering almost $1 billion total annual sales and a major patient share in all six major pharmaceutical markets we cover by the end of our forecast period. DCVax-L and ICT-107, which are extremely pricey personalized treatments and will face competition from immune checkpoint inhibitors, will experience modest uptake in the first-line setting.

INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market

Got a question about the product? Email us at [email protected] or ask the author directly by using the form to the right. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Pharma Disease Insight: Glioma PowerPoint document

This document is available as part of the following discount bundle(s):

Pharma Disease Insight Oncology Bundle
 

Pharma Disease Insight: Glioma

Sold by BigPharma2000 (this author has 41 documents)

$99.00

ALL FEES INCLUDED
Add to Cart
  

This business document is categorized under the function(s):

It applies to Healthcare & Life Sciences

File Type: PowerPoint (pptx)

File Size: 1.9 MB

Number of Slides: 34 (includes cover, transition slides)

Purchase includes lifetime product updates. After your purchase, you will receive an email to download this document.

Initial upload date (first version): Jun 8, 2017
Most recent version published: Jun 8, 2017

Ask the Author a Question

Must be logged in Click here to log in






CUSTOMER TESTIMONIALS




SELECT CUSTOMERS

Since 2012, we have provided best practices to over 5,000 businesses and organizations of all sizes across the world—in over 130 countries. Below is just a very small sample of our customer base.



Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.



CUSTOMERS ALSO BOUGHT THESE DOCUMENTS

79-slide PowerPoint deck
$99.00
Author: ILMAM
407-slide PowerPoint deck
$199.00
Author: LearnPPT
102-slide PowerPoint deck and supporting Excel workbook
$79.00
5-page Word document and supporting Word
$29.00
147-slide PowerPoint deck and supporting Excel workbook
$69.00
32-slide PowerPoint deck and supporting Excel workbook
$49.00
Author: LearnPPT
56-slide PowerPoint deck
$65.00
81-slide PowerPoint deck
$59.00
Author: LearnPPT
56-slide PowerPoint deck
$59.00
Author: ILMAM

 
RELATED TOPICS

TOP 10 TOPICS

Become your organization's resident expert on...

Digital Transformation
 
Strategy Development
 
Organizational Design (OD)
 
Performance Management
 
Post-merger Integration (PMI)
 
Organizational Culture (OC)
 
Business Transformation
 
Innovation Management
Interested in something else? Browse our 350+ Business Toolkits of best practices, each focused on a specific management topic.